(Q36934791)

17 August 2017

1 reference

title

Targeted therapies in bladder cancer--an update (English)

1 reference

17 August 2017

Peter C Black

1

1 reference

PubMed ID

17826665

17 August 2017

Piyush K Agarwal

series ordinal

2

1 reference

PubMed ID

17826665

17 August 2017

Colin P N Dinney

series ordinal

3

1 reference

17 August 2017

1 September 2007

1 reference

17 August 2017

6

1 reference

based on heuristic

inferred from page(s)

published in

Urologic Oncology

1 reference

17 August 2017

25

1 reference

17 August 2017

433-438

1 reference

17 August 2017

5

1 reference

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

The voiding pattern in infants with dilating reflux

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Erlotinib in previously treated non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Molecular correlates of gefitinib responsiveness in human bladder cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Cell responses to FGFR3 signalling: growth, differentiation and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

A new strategy in the war on renal cell cancer: hitting multiple targets with limited collateral damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

Sorafenib for the treatment of advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.05.011

10.1016/J.UROLONC.2007.05.011

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17826665